Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia
Abstract Background Coronavirus disease‐19 (COVID‐19) “lockdowns” caused an abruptly restricted access to health care services such as immunotherapy for allergic rhinitis (AR) and led to higher exposure to indoor allergens. This study aimed to assess the impact of COVID‐19 lockdowns on AR symptoms r...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | Laryngoscope Investigative Otolaryngology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/lio2.738 |
| _version_ | 1828380989152296960 |
|---|---|
| author | Lucia C. Pérez‐Herrera Sebastián Ordoñez‐Cerón Sergio Moreno‐López Daniel Peñaranda Elizabeth García Augusto Peñaranda |
| author_facet | Lucia C. Pérez‐Herrera Sebastián Ordoñez‐Cerón Sergio Moreno‐López Daniel Peñaranda Elizabeth García Augusto Peñaranda |
| author_sort | Lucia C. Pérez‐Herrera |
| collection | DOAJ |
| description | Abstract Background Coronavirus disease‐19 (COVID‐19) “lockdowns” caused an abruptly restricted access to health care services such as immunotherapy for allergic rhinitis (AR) and led to higher exposure to indoor allergens. This study aimed to assess the impact of COVID‐19 lockdowns on AR symptoms reported by the patients treated with immunotherapy who attended the Hospital Fundación Santa Fe de Bogotá and Unidad Médico Quirúrgica de Otorrinolaringología, Colombia. Methods Pre–post study that included patients with AR confirmed diagnosis (prick test), treated with immunotherapy before and after COVID‐19 lockdowns on March–June 2020. Visual analog scales (VAS) and sociodemographic questionnaires were applied to assess AR symptoms (nasal obstruction, pruritus, rhinorrhea, and ocular symptoms) and their associated factors. Results A total of 318 participants were included, and their mean age was 18.9 years (SD: 12.8). The median number of immunotherapy doses applied before isolation was 11 (interquartile range [IQR]: 6–19), and the median number of immunotherapy doses missed during isolation was three doses (IQR: 2–3). Up to 38.4% of the AR patients reported that their symptoms got worse during lockdowns. A pre–post mean difference in the VAS score of 0.5 was found for nasal obstruction (p = .01), 0.7 for pruritus (p < .001), 0.7 points for rhinorrhea (p < .001), and 0.8 for ocular symptoms (p < .001). Factors associated with worsening of AR symptom scores were pet ownership, atopic dermatitis, lower educational level, and a low number of immunotherapy doses applied before lockdowns. Conclusion A large proportion of patients reported worsening of their AR symptoms, probably due to higher exposure to indoor AR allergens and interruption of immunotherapy during COVID‐19 lockdowns. |
| first_indexed | 2024-12-10T04:07:37Z |
| format | Article |
| id | doaj.art-35edafae9ef54e0c83b057c2a228631b |
| institution | Directory Open Access Journal |
| issn | 2378-8038 |
| language | English |
| last_indexed | 2024-12-10T04:07:37Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Laryngoscope Investigative Otolaryngology |
| spelling | doaj.art-35edafae9ef54e0c83b057c2a228631b2022-12-22T02:02:48ZengWileyLaryngoscope Investigative Otolaryngology2378-80382022-04-017230531510.1002/lio2.738Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, ColombiaLucia C. Pérez‐Herrera0Sebastián Ordoñez‐Cerón1Sergio Moreno‐López2Daniel Peñaranda3Elizabeth García4Augusto Peñaranda5Otolaryngology and Allergology Research groups Unidad Médico Quirúrgica de Otorrinolaringología (UNIMEQ‐ORL) Bogotá ColombiaOtolaryngology and Allergology Research groups Unidad Médico Quirúrgica de Otorrinolaringología (UNIMEQ‐ORL) Bogotá ColombiaOtolaryngology and Allergology Research groups Unidad Médico Quirúrgica de Otorrinolaringología (UNIMEQ‐ORL) Bogotá ColombiaOtolaryngology Section Fundación Universitaria de Ciencias de la Salud Bogotá ColombiaOtolaryngology and Allergology Research groups Unidad Médico Quirúrgica de Otorrinolaringología (UNIMEQ‐ORL) Bogotá ColombiaOtolaryngology and Allergology Research groups Unidad Médico Quirúrgica de Otorrinolaringología (UNIMEQ‐ORL) Bogotá ColombiaAbstract Background Coronavirus disease‐19 (COVID‐19) “lockdowns” caused an abruptly restricted access to health care services such as immunotherapy for allergic rhinitis (AR) and led to higher exposure to indoor allergens. This study aimed to assess the impact of COVID‐19 lockdowns on AR symptoms reported by the patients treated with immunotherapy who attended the Hospital Fundación Santa Fe de Bogotá and Unidad Médico Quirúrgica de Otorrinolaringología, Colombia. Methods Pre–post study that included patients with AR confirmed diagnosis (prick test), treated with immunotherapy before and after COVID‐19 lockdowns on March–June 2020. Visual analog scales (VAS) and sociodemographic questionnaires were applied to assess AR symptoms (nasal obstruction, pruritus, rhinorrhea, and ocular symptoms) and their associated factors. Results A total of 318 participants were included, and their mean age was 18.9 years (SD: 12.8). The median number of immunotherapy doses applied before isolation was 11 (interquartile range [IQR]: 6–19), and the median number of immunotherapy doses missed during isolation was three doses (IQR: 2–3). Up to 38.4% of the AR patients reported that their symptoms got worse during lockdowns. A pre–post mean difference in the VAS score of 0.5 was found for nasal obstruction (p = .01), 0.7 for pruritus (p < .001), 0.7 points for rhinorrhea (p < .001), and 0.8 for ocular symptoms (p < .001). Factors associated with worsening of AR symptom scores were pet ownership, atopic dermatitis, lower educational level, and a low number of immunotherapy doses applied before lockdowns. Conclusion A large proportion of patients reported worsening of their AR symptoms, probably due to higher exposure to indoor AR allergens and interruption of immunotherapy during COVID‐19 lockdowns.https://doi.org/10.1002/lio2.738allergic rhinitisCOVID‐19immunotherapylockdownSARS‐CoV2 |
| spellingShingle | Lucia C. Pérez‐Herrera Sebastián Ordoñez‐Cerón Sergio Moreno‐López Daniel Peñaranda Elizabeth García Augusto Peñaranda Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia Laryngoscope Investigative Otolaryngology allergic rhinitis COVID‐19 immunotherapy lockdown SARS‐CoV2 |
| title | Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia |
| title_full | Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia |
| title_fullStr | Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia |
| title_full_unstemmed | Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia |
| title_short | Impact of the COVID‐19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in Bogotá, Colombia |
| title_sort | impact of the covid 19 national lockdown in the allergic rhinitis symptoms in patients treated with immunotherapy at two allergy referral centers in bogota colombia |
| topic | allergic rhinitis COVID‐19 immunotherapy lockdown SARS‐CoV2 |
| url | https://doi.org/10.1002/lio2.738 |
| work_keys_str_mv | AT luciacperezherrera impactofthecovid19nationallockdownintheallergicrhinitissymptomsinpatientstreatedwithimmunotherapyattwoallergyreferralcentersinbogotacolombia AT sebastianordonezceron impactofthecovid19nationallockdownintheallergicrhinitissymptomsinpatientstreatedwithimmunotherapyattwoallergyreferralcentersinbogotacolombia AT sergiomorenolopez impactofthecovid19nationallockdownintheallergicrhinitissymptomsinpatientstreatedwithimmunotherapyattwoallergyreferralcentersinbogotacolombia AT danielpenaranda impactofthecovid19nationallockdownintheallergicrhinitissymptomsinpatientstreatedwithimmunotherapyattwoallergyreferralcentersinbogotacolombia AT elizabethgarcia impactofthecovid19nationallockdownintheallergicrhinitissymptomsinpatientstreatedwithimmunotherapyattwoallergyreferralcentersinbogotacolombia AT augustopenaranda impactofthecovid19nationallockdownintheallergicrhinitissymptomsinpatientstreatedwithimmunotherapyattwoallergyreferralcentersinbogotacolombia |